ASH 2021

Acute Lymphoblastic Leukaemia

New Interfant protocol includes blinatumomab for KMT2A-r ALL

Presented By

Dr Inge van der Sluis, Princess Máxima Center for Pediatric Oncology, the Netherlands

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 12:00

Persistent disparities in ALL health outcomes

Presented By

Dr Sumit Gupta, University of Toronto, Canada

Trial

COG ALL

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:59

EWALL-INO: Inotuzumab ozogamicin promising as first-line therapy for BCP-ALL

Presented By

Prof. Patrice Chevallier, Nantes University Hospital, France

Trial

Phase 2, EWALL-INO

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:57

UKALL 2003: Therapy de-escalation safe in low-risk MRD patients with ALL

Presented By

Dr Sujith Samarasinghe, Great Ormond Street Hospital, UK

Trial

UKALL 2003

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:55

Acute Myeloid Leukaemia

AMLSG 16-10: Long-term benefits of midostaurin for FLT3-ITD-mutated AML

Presented By

Dr Hartmut Döhner, Universitätsklinikum Ulm, Germany

Trial

Phase 2, AMLSG 16-10

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:53

Comparable effectiveness of CPX-351 and venetoclax plus HMA in older AML patients

Presented By

Dr Justin Grenet, Weill Cornell Medical Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:51

Promising frontline triplet regimen for TP53-mutated AML

Presented By

Dr Naval Daver, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:49

Encouraging results of novel triplet combination for AML

Presented By

Dr Patrick Reville, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:48

Heavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen

Presented By

Dr Musa Yilmaz, MD Anderson Cancer Center, TX, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:46

Benefits of eprenetapopt plus azacitidine for TP53-mutant MDS and oligoblastic AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center, FL, USA

Trial

Phase 2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:44

Improved risk stratification in MDS via gene-based scoring system

Presented By

Dr Elsa Bernard, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:43

Chronic Leukaemia

CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL

Presented By

Dr Paolo Ghia, Università Vita-Salute San Raffaele, Italy

Trial

Phase 2, CAPTIVATE

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:41

SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL

Presented By

Prof. Constantine Tam, Peter MacCallum Cancer Centre, Australia

Trial

Phase 3, SEQUOIA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:39

Investigational therapies superior to standard-of-care in double-exposed CLL

Presented By

Dr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:36

Multiple Myeloma

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By

Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 2, GRIFFIN

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:30

MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM

Presented By

Prof. Philippe Moreau, University Hospital of Nantes, France

Trial

Phase 1/2, MajesTEC-1

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:26

iStopMM: Smouldering MM highly prevalent in general population

Presented By

Dr Sigrún Thorsteinsdóttir, University of Iceland, Iceland

Trial

iStopMM

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:25

Mechanisms of D-KRd treatment failure in MM identified

Presented By

Dr Eileen Boyle, NYU Langone Health, NY, USA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:22

TRIMM-2: Favourable results of talquetamab plus daratumumab for MM

Presented By

Dr Ajai Chari, Mount Sinai School of Medicine, NY, USA

Trial

Phase 1, TRIMM-2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:16

Lymphoma

Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma

Presented By

Dr Michael Bishop, University of Chicago, IL, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:11

Axi-cel improved event-free survival in R/R DLBCL

Presented By

Dr Frederick Locke, Moffitt Cancer Cancer, FL, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:09

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:01

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By

Prof. Hervé Tilly, University of Rouen, France

Trial

Phase 3, POLARIX

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:56

Novel non-invasive biomarker ctDNA shows value in CNS lymphoma

Presented By

Dr Jurik Mutter, University Medical Center Freiburg, Germany

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 10:53

Myeloproliferative Neoplasms

Immune Thrombocytopenia

Haemophilia

Clonal Haematopoiesis